THERAPEUTIC MANAGEMENT OF HYPERTENSION AND HYPERLIPIDEMIA IN TYPE-2 DIABETES MELLITUS PATIENTS IN SOUTHWESTERN REGION OF SAUDI ARABIA: A PHARMACIST PERSPECTIVE
Â Objective: The main objective of this study was to evaluate the therapeutic management of hypertension (HTN) and hyperlipidemia in Type 2 diabetes mellitus (T2DM) patients in Aseer Diabetic Center, southwestern region of Saudi Arabia.
Methods: This is a cross-sectional retrospective study in adult T2DM patients. A total number of 343 patient's records was randomly selected from the patient medical records section. Among the 343 T2DM patients, all were hyperlipidemics, and only 228 patients were Hypertensive. The collected raw data were recorded and statistically analyzed with Windows Microsoft Excel 2007. Descriptive statistics of mean, standard deviation, and frequencies were performed on the sample, one-way ANOVA was used to analyze the continuous data by using Graphpad software version-5; pâ‰¤0.05 was considered statistically significant.
Result: The systolic blood pressure (BP) was found to have statistically significant difference (pâ‰¤0.0320) after treatment, but there is no statistical difference in diastolic BP. Glycemic control was found to have statistically significant difference (pâ‰¤0.0039). Most of the patients were treated with captopril -25 mg (angiotensin-converting enzyme inhibitor class drug). All the lipid profile high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and total cholesterol showed statistically significant difference after treatment except triglycerides. Most of the patients were prescribed with statins for hyperlipidemia.
Conclusion: In this study, systolic HTN is better controlled with statistically significant difference compared to diastolic HTN. In the current study, lipid control was better than glycemic control. Updating of the drug formulary to have new therapeutic agents can improve the current status.
Keywords: Hyperlipidemia, Hypertension, Saudi Arabia Southwestern region, Therapeutic management, Type 2 diabetes.
Zaki NM, Maghrabi I. Trends in therapeutic interventions in patients with diabetes mellitus in Saudi Arabia. Int J Pharm Pharm Sci 2013;5(3):171-7.
Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001;414(6865):782-7.
Mancia G. The association of hypertension and diabetes: Prevalence, cardiovascular risk and protection by blood pressure reduction. Acta Diabetol 2005;42 Suppl 1:S17-25.
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 2003;289(19):2560-72.
American Diabetes Association. Standards of medical care in diabetes, 2010. Diabetes Care 2010;34:S11-61.
Pinto LC, Ricardo ED, LeitÃ£o CB, Kramer CK, Zanatta CM, Gross JL, et al. Inadequate blood pressure control in patients with type 2 diabetes mellitus. Arq Bras Cardiol 2010;94(5):651-5.
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998;317(7160):703-13.
Knapp DA. Development of criteria for drug utilization review. Clin Pharmacol Ther 1991;50:600-2.
WHO. How to Investigate Drug Use in Health Facilities: Selected Drug Use Indicators. Vol. 1. Geneva: World Health Organization WHO/DAP; 1993. p. 1-87.
Naryan D, Patra VJ, Dinda SC. Diabetes and Indian traditional medicines: An overview. Int J Pharm Pharm Sci 2012;4(3):45-53.
American Diabetes Association. Standards of medical care in diabetes-2013. Diabetes Care 2013;36(1): S11-66.
Alhyas L, McKay A, Balasanthiran A, Majeed A. Prevalences of overweight, obesity, hyperglycaemia, hypertension and dyslipidaemia in the Gulf: Systematic review. JRSM Short Rep 2011;2(7):55.
Makaryus AN, McFarlane SI. Treatment of hypertension in the diabetic patient. Therapy 2009;6(4):497-505.
Eckel RH. Diabetic dyslipidemia and cardiovascular risk. Curr Diabetes Rep 2008;8(6):421-3.
Liebson PR. Diabetes control and cardiovascular risk: ACCORD, ADVANCE, AVOID, and SANDS. Prev Cardiol 2008;11(4):230-6.
Kuznik A, Mardekian J. Trends in utilization of lipid- and blood pressure-lowering agents and goal attainment among the U.S. diabetic population, 1999-2008. Cardiovasc Diabetol 2011;10:31.
Zaman Huri H, Lee QY, Pendek R, Sulaiman CZ. Use of antiplatelet agents for primary and secondary prevention of cardiovascular disease amongst type 2 diabetic patients. J Pharm Pract 2008;21(4):287-301.
Abdel-Gayoum AG. The effect of glycemic control in type 2 diabetic patients with diabetes-related dyslipidemia. Saudi Med J 2004;25(2):207-11.
Stehbens WE. The epidemiological relationship of hypercholesterolemia, hypertension, diabetes mellitus and obesity to coronary heart disease and atherogenesis. J Clin Epidemiol 1990;43(8):733-41.
Fuller CJ, Chandalia M, Garg A, Grundy SM, Jialal I. RRR-alpha-tocopheryl acetate supplementation at pharmacologic doses decreases low-density-lipoprotein oxidative susceptibility but not protein glycation in patients with diabetes mellitus. Am J Clin Nutr 1996;63(5):753-9.
Khurram M, Gul H, Rahman FU, Khar HT, Faheem M. Lipid abnormalities in patients with type 2 diabetes. J Rawalpindi Med Coll (JRMC) 2013;17(2):167-8.
Al-Nozha MM, Al-Maatouq MA, Al-Mazrou YY, Al-Harthi SS, Arafah MR, Khalil MZ, et al. Diabetes mellitus in Saudi Arabia. Saudi Med J 2004;25(11):1603-10.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352(9131):837-53.
United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995;310(6972):83-8.
U.K. prospective diabetes study 16. Overview of 6 yearsâ€™ therapy of type II diabetes: A progressive disease. U.K. Prospective Diabetes Study Group. Diabetes 1995;44(1):1249-58.
Alwakeel JS, Sulimani R, Al-Asaad H, Al-Harbi A, Tarif N, Al Suwaida A, et al. Diabetes complications in 1952 type 2 diabetes mellitus patients managed in a single institution in Saudi Arabia. Ann Saudi Med 2008;28(4):260-6.
Akbar DH. Is hypertension common in hospitalized type 2 diabetic patients? Saudi Med J 2001;22(2):139-41.
Vijan S, Hayward RA. Treatment of hypertension in type 2 diabetes mellitus: Blood pressure goals, choice of agents, and setting priorities in diabetes care. Ann Intern Med 2003;138(7):593-602.
Campbell NR, Gilbert RE, Leiter LA, Larochelle P, Tobe S, Chockalingam A, et al. Hypertension in people with type 2 diabetes: Update on pharmacologic management. Can Fam Physician 2011;57(9):997-1002, e347-53.
Datta S, Udupa A.L. Antihypertensive drug use in patients havingcomorbid diabetes: Cross sectional prescription pattern study in a tertiary care hospital. Asian J Pharm Clin Res 2010;3(4):43-5.
Al-Rowais NA. Glycemic control in diabetic patients in King Khalid University Hospital (KKUH) - Riyadh - Saudi Arabia. Saudi Pharm J 2014;22(3):203-6.
Barrett-Connor E, Wingard DL. Sex differential in ischemic heart disease mortality in diabetics: A prospective population-based study. Am J Epidemiol 1983;118(4):489-96.
Adinortey MB, Gyan BE, Adjimani J, Nyarko P, Sarpong C, Tsikata FY, et al. Dyslipidaemia associated with type 2 diabetics with micro and macrovascular complications among Ghanaians. Indian J Clin Biochem 2011;26(3):261-8.
Bello-Sani F, Bakari AG, Anumah FE. Dyslipidaemia in persons with type 2 diabetes mellitus in Kaduna, Nigeria. Int J Diabetes Metab 2007;15:9-13.
Onyemelukwe GC, Stafford WL. Serum lipids in Nigerians: The effect of diabetes mellitus. Trop Geogr Med 1981;33(4):323-8.
Talbert RL. Pharmacotherapy A Pathophysiologic Approach. 7th ed. New York: McGraw Hill; 2009. p. 38-408.
Adepu R, Madhu S. Influence of post discharge counseling on health outcomes in diabetic and hypertensive patients. Asian J Pharm Clin Res 2011;4(3):28-33.
How to Cite
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.